ClinicaliQ Trial Snapshot
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors — Active Not Recruiting • Phase I • Oncology • NCT05277051.
- New cancer drug GSK4381562 tested for first time in humans with advanced tumours to check safety and how the body processes it.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted. Conditions: Neoplasms Interventions: Remzistotug, Dostarlimab, Belrestotug, Nelistotug, GSK5764227 Lead Sponsor: GlaxoSmithKline Planned Enrollment: 152 participants